[1] PRIETO J,MELERO I,SANGRO B.Immunological landscape and immunotherapy of hepatocellular carcinoma[J].Nat Rev GastroenterolHepatol,2015,12(12):681-700.
[2] 周雪峰.谷氨酰胺与肿瘤免疫、化学治疗、放射治疗[J].国外医学外科学,2002,29(6):334-336.
[3] OH M H,SUN I H,ZHAO L,et al.Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells[J].The Journal of Clinical Investigation,2020,130(7):3865-3884.
[4] GETTINGER S N,HORN L,GANDHI L,et al.Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody,BMS-936558,ONO-4538) in patients with previously treated advanced non-small-cell lung cancer[J].Journal of Clinical Oncology,2015,33(18):2004-2012.
[5] RIZVI N A,MAZIōRES J,PLANCHARD D,et al.Activity and safety of nivolumab,an anti-PD-1 immune checkpoint inhibitor,for patients with advanced,refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2,single-arm trial[J].The Lancet Oncology,2015,16(3):257-265.
[6] 刘宇佳,张轶雯,钟里科,等.肿瘤微环境对肿瘤代谢的影响及研究进展[J].肿瘤学杂志,2020,26(1):47-52.
[7] ATREYA C E,TURNBAUGH P J.Probing the tumor micro (b) environment[J].Science,2020,368(6494):938-939.
[8] 李佳颖,胡雨婷.代谢重编程与近端肾小管损伤的研究进展[J].中华肾脏病杂志,2020,36(11):892-896.
[9] 姚利昂,胡泽平.瘤代谢重编程与药物耐药性[J].中国医学前沿杂志,2019,11(2):23-27.
[10] PAWLIK T M,SOUBA W W,SWEENEY T J,et al.Amino acid uptake and regulation in multicellular hepatoma spheroids[J].Journal of Surgical Research,2000,91(1):15-25.
[11] TAO J,ZHANG R,SINGH S,et al.Targeting β-catenin in hepatocellular cancers induced by coexpression of mutant β-catenin and K-Ras in mice[J].Hepatology,2017,65(5):1581-1599.
[12] CIEPLY B,ZENG G,PROVERBS-SINGH T,et al.Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene[J].Hepatology,2009,49(3):821-831.
[13] REBOUISSOU S,FRANCONI A,CALDERARO J,et al.Genotype-phenotype correlation of CTNNB1 mutations reveals different β-catenin activity associated with liver tumor progression[J].Hepatology,2016,64(6):2047-2061.
[14] LIU P,LU D,AL-AMERI A,et al.Glutamine synthetase promotes tumor invasion in hepatocellular carcinoma through mediating epithelial-mesenchymal transition[J].Hepatology Research,2020,50(2):246-257.
[15] 梁宝瑜,金春,高俪原,等.谷氨酰胺转运蛋白ASCT2的研究进展[J].中国药理学通报,2020,36(1):22-25.
[16] BAR-PELED L,SABATINI D M.Regulation of mTORC1 by amino acids[J].Trends in Cell Biology,2014,24(7):400-406.
[17] BOND P.Regulation of mTORC1 by growth factors,energy status,amino acids and mechanical stimuli at a glance[J].Journal of the International Society of Sports Nutrition,2016,13(1):1-11.
[18] ZHANG M,FU Y,CHEN Y,et al.Inhibition of the mTORC1/NF-κB axis alters amino acid metabolism in human hepatocytes[J].BioMed Research International,2021,2021:862146.
[19] 万燕萍.谷氨酰胺对人肝癌细胞系SMMC-7721增殖影响的体外研究[J].胃肠病学,2005,10(3):148-152.
[20] ZHONG X,LI W,HUANG X,et al.Effects of glutamine supplementation on the immune status in weaning piglets with intrauterine growth retardation[J].Archives of Animal Nutrition,2012,66(5):347-356.
[21] DIETL K,RENNER K,DETTMER K,et al.Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes[J].The Journal of Immunology,2010,184(3):1200-1209.
[22] PALSSON-MCDERMOTT E M,CURTIS A M,Goel G,et al.Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages[J].Cell Metabolism,2015,21(1):65-80.
[23] WEI H R,GAO P.Regulation of cancer cell metabolism[J].Scientia Sinica Vitae,2017,47(1):132-139.
[24] PALSSON-MCDERMOTT E M,DYCK L,ZASLONA Z,et al.Pyruvate kinase M2 is required for the expression of the immune checkpoint PD-L1 in immune cells and tumors[J].Frontiers in Immunology,2017,8:1300.
[25] EL-ANSARI R,CRAZE M L,ALTHOBITI M,et al.Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer[J].British Journal of Cancer,2020,122(1):94-101.
[26] MA G,IANG Y,CHEN Y,et al.Glutamine deprivation induces PD-L1 expression via activation of EGFR/ERK/c-Jun signaling in renal cancer[J].Molecular Cancer Research,2020,18(2):324-339.
[27] CHEN N,FANG W,ZHANG J,et al.Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC:implication for optional immune targeted therapy for NSCLC patients with EGFR mutation[J].Journal of Thoracic Oncology,2015,10(6):910-923.
[28] INAMURA K,YOKOUCHI Y,SAKAKIBARA R,et al.Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma[J].Japanese Journal of Clinical Oncology,2016,46(10):935-941.
[29] WANG L,YANG X,LI D,et al.The elevated glutaminolysis of bladder cancer and T cells in a simulated tumor microenvironment contributes to the up-regulation of PD-L1 expression by interferon-γ[J].OncoTargets and Therapy,2018,11:7229-7243.
[30] JIN H,WANG S,ZAAL E A,et al.A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer[J].Elife,2020,9:e56749.
[31] DAI W,XU L,YU X,et al.OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism[J].Journal of Hepatology,2020,72(5):909-923.
[32] LEONE R D,ZHAO L,ENGLERT J M,et al.Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion[J].Science,2019,366(6468):1013-1021.
[33] SHARMA N S,GUPTA V K,GARRIDO V T,et al.Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy[J].The Journal of Clinical Investigation,2020,130(1):451-465.
[34] MASSARD C,GORDON M S,SHARMAS,et al.Safety and efficacy of durvalumab (MEDI4736),an anti-programmed cell death ligand-1 immune checkpoint inhibitor,in patients with advanced urothelial bladder cancer[J].Journal of Clinical Oncology,2016,34(26):3119.
[35] EL-KHOUEIRY A B,YAU T,KANG Y K,et al.Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC):long-term results from CheckMate 040[J].Journal of Clinical Oncology,2021,39(3):269.
[36] MERLE P,EDELINE J,BOUATTOUR M,et al.Pembrolizumab (pembro)vs. placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib:updated data from the randomized,phase Ⅲ KEYNOTE-240 study[J].Journal of Clinical Oncology,2021,39(3):268.
[37] BYUN J K,PARK M,LEE S,et al.Inhibition of glutamine utilization synergizes with immune checkpoint inhibitor to promote antitumor immunity[J].Molecular Cell,2020,80(4):592-606.
[38] VARGHESE S,PRAMANIK S,WILLIAMS L J,et al.The glutaminase inhibitor CB-839(Telaglenastat) enhances the antimelanoma activity of T-Cell-Mediated immunotherapies[J].Mol Cancer Ther,2021,20(3):500-511. |